Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Stevanato Group said 2026 performance is tracking its original expectations, with its BDS segment expected to deliver double-digit constant-currency growth and approximately 9% reported growth for the full year. The Engineering business is also on plan, with third-party revenue expected in a €130 million-€140 million range versus €138 million previously cited; the segment represents about 11%-12% of group revenue. Management’s comments reinforce its existing growth outlook rather than signaling a material guidance revision.

Analysis

The investable issue is mix rather than the headline growth rate. A larger contribution from BDS should improve earnings quality if utilization rises, because recurring drug-delivery components carry materially better visibility and typically better incremental margins than project-based engineering revenue. However, the disclosed engineering range implies little room for a recovery surprise this year; any valuation re-rating will require evidence that BDS growth converts into margin expansion and cash generation rather than being absorbed by capacity ramp costs.

Near term, this is unlikely to change consensus estimates materially without new order, utilization, or margin disclosures. The key 1-3 month catalyst is third-quarter execution: BDS organic growth, gross-margin progression, and backlog/book-to-bill are more important than reported revenue given FX translation. A weak point is customer concentration and biologics/GLP-1 capital-spending cyclicality: delayed fill-finish programs could impair equipment demand before consumables offset it.

Over 6-18 months, STVN is a differentiated beneficiary of the shift toward injectable therapies and high-value self-administration formats, but the market may be underestimating the capital intensity required to serve that demand. The contrarian view is that a recurring-revenue narrative can be premature if growth is driven by a limited number of launch programs; sustained margin uplift, not double-digit BDS growth alone, is the proof point. Watch for BDS growth falling below low double digits, engineering revenue below the guided range, or a guide-down in EBITDA margin as thesis falsifiers.

Key Decisions for Investors

• Maintain STVN on a tactical long watchlist rather than chase conference commentary. Initiate only after Q3 confirms double-digit constant-currency BDS growth plus positive gross-margin or EBITDA-margin progression; target a 3-6 month rerating on improved earnings quality, with exit if BDS decelerates below 10% or engineering falls below EUR130m.
• For a relative-value expression, consider long STVN / short a broad life-sciences tools proxy such as XBI only after execution confirmation. The thesis is injectable-device exposure versus biotech funding beta; size modestly because STVN's customer/program concentration can dominate sector correlations.
• Do not underwrite a standalone engineering recovery in 2026. Treat equipment backlog, book-to-bill, capacity utilization, and customer prepayment trends as required diligence items before adding exposure; absent those data, the stated outlook is insufficient to support a high-conviction multiple expansion thesis.
• Monitor major injectable-drug launch cadence and fill-finish capacity announcements over the next two quarters. A broad delay in GLP-1, biologics, or vaccine program commercialization would be an early warning for STVN's future consumables pull-through and warrants reducing any long exposure.